Abstract:Background: Polymer-free drug-eluting stents (DES) without permanent-polymer coating may be associated with rapid vessel healing, providing a rationale to reduce dual-antiplatelet therapy (DAPT). The aim of the current study was to compare vessel healing of a polymer-free sirolimus-eluting stent (PF-SES), its bare metal stent (BMS) analogue to a permanent polymer-based sirolimus-eluting stent (SES) with proven effectiveness in porcine coronary arteries. Material and methods: An ultrathin-strut cobalt–chromium PF-SES, its BMS analogue and an SES with a permanent polymer were used to study vessel healing and their antistenotic potential. Stents were implanted in porcine coronary arteries for histopathologic analysis at 7, 28 and 180 days. In an additional in vitro study, the thrombogenicity of PF-SES was compared with a fluoropolymer-coated everolimus-eluting stent (EES) which demonstrated low stent thrombosis rates in numerous studies. Results: In the animal study, neointimal growth and injury scores were minimal and inflammation scores were low in the neointima and adventitia in all study groups. After 28 days, neointimal area was lowest in PF-SES when compared with SES and BMS (1.48 ± 0.55 mm2 versus 2.43 ± 0.69 mm2 versus 1.90 ± 0.85 mm2, respectively, p 0.05). At 180 days, neointimal area and thickness were most pronounced in SES ( p < 0.05) and comparable with BMS implantations, which were characterized by nearly completed vessel healing. PF-SES and BMS had complete endothelialization, absence of fibrin and sustained low inflammatory reaction when compared with the permanent polymer-based SES (inflammation score: PF-SES 0.41 ± 0.74 versus SES 2.52 ± 1.72 versus BMS 0.30 ± 0.65, respectively, p 0.05). In the in vitro thrombogenicity study, the PF-SES confirmed comparable antithrombogenic properties with regard to the parameters fibrin and platelet binding, and platelet aggregation when compared with the EES. Conclusions: As compared with BMS, the ultrathin-strut cobalt–chromium PF-SES showed similar endothelialization at 28 days and comparable healing characteristics at 180 days efficacious inhibition of neointimal proliferation in porcine coronary arteries with low inflammation responses and a BMS-like endothelialization at 180 days. In addition, in an in vitro model, the PF-SES also confirmed low thrombogenicity as compared with the EES.

Evaluation of a Novel Paclitaxel-Eluting Stent with a Bioabsorbable Polymeric Surface Coating in the Porcine Artery Injury Model

In Vitro and in Vivo Characterization of A Coronary Stent Coated with an Elastic Biodegradable Polymer for the Sustained Release of Paclitaxel

Polymer-free Dual Drug-Eluting Stents Evaluated in a Porcine Model

Impact of Fluoropolymer-Based Paclitaxel Delivery on Neointimal Proliferation and Vascular Healing: A Comparative Peripheral Drug-Eluting Stent Study in the Familial Hypercholesterolemic Swine Model of Femoral Restenosis

The Prevention of Restenosis in Vivo with a VEGF Gene and Paclitaxel Co-Eluting Stent

6-Month Follow-Up of a Novel Biodegradable Drug-Eluting Stent Composed of Poly-L-Lactic Acid and Amorphous Calcium Phosphate Nanoparticles in Porcine Coronary Artery.

Poly-L-Lactic Acid/Amorphous Calcium Phosphate Bioabsorbable Stent Causes Less Inflammation Than Poly-L-Lactic Acid Stent in Coronary Arteries

Study on the effect of restenosis of the stent coated with PEG-PLA-PGL/RGD after PCI

Paclitaxel-eluting Stent Inhibits Restenosis in Peripheral Artery in a Swine Model of Diabetes: an Experiment Study

VASCULAR RESPONSE OF A POLYMER-FREE, PACLITAXEL-COATED STENT (ZILVER PTX) VERSUS A POLYMER-COATED, PACLITAXEL-ELUTING STENT (ELUVIA) IN HEALTHY SWINE ILIOFEMORAL ARTERIES

Long-Term Effects of Novel Biodegradable, Polymer-Coated, Sirolimus-Eluting Stents on Neointimal Formation in A Porcine Coronary Model

Safety and Efficacy of a Non-Polymeric Paclitaxel-Eluting Microporous Stent in Real-World Percutaneous Coronary Intervention.

Safety and efficacy of polymer-free paclitaxel-eluting microporous stent in real-world practice: 1-year follow-up of the SERY-I registry.

A cell membrane like biomimetic drug-eluting coronary stent

Evaluation of a novel polymer-free sirolimus-eluting stent in a porcine model

A Novel Paclitaxel Eluting Bioresorbable Coronary Stent 3D Printed from a Tougher and Faster Degradation Poly(L-Lactide-Co-Caprolactone) Co-Polymer

Drug-Eluting Biodegradable Poly-D/L-Lactic Acid Vascular Stents: An Experimental Pilot Study

AS-30: the Preclinical Assessment of a Novel Biodegradable Rapid Prohealing Polymer with Sirolimus -Eluting Coating Stent in Porcine Model

Efficacy and Safety of a Novel Nano-Porous Polymer-Free Sirolimus-Eluting Stent in Pigs.

Mid-Term Outcomes of Novel Covered Stent with Biodegradable Membrane in Porcine Coronary Artery Perforation

Comparative preclinical evaluation of a polymer-free sirolimus-eluting stent in porcine coronary arteries